Impact and function of the mitochondria transcription factor A (TFAM) in sepsis

Not Applicable

• Conditions: healthy volunteers; A41.9; Sepsis, unspecified

• Registration Number: DRKS00015619
• Lead Sponsor: niversitätsklinikum Knappschaftskrankenhaus Bochum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-10-08
• Study Completion: 2019-01-21
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

voluntary; healthy individuals age >18, <65, no risk for blood drawing

Exclusion Criteria

low body weight (< 50 kg), too young age <18 and too old age>65, anemia, anamnestic incompatibility of blood drawing

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluation of the ratio of the mitochondrial and cytosolic concentration of TFAM beofre LPS stimulation and after LPS stimualtion during the time course (after 1/2, 4, 24, 48 hours) by western blot.

Secondary Outcome Measures

Name	Time	Method
Evalutaion of the expression of mitochondrial mRNA, mRNA of TFAM and the regulation proteins (NFkB, PGC-1a, NRF1, NRF2) during the time course (after 1/2, 4, 24, 48 hours) by RT-PCR and Elisa.<br>Furthermore the different TFAM Expression and distribution will be observerd in surivors compared to non-survivors after 30 days.